Flurbiprofen transdermal

Drug Profile

Flurbiprofen transdermal

Alternative Names: Transact LAT transdermal system; TransAct-LAT

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Amdipharm
  • Class Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 21 Oct 2015 Amdipharm has been acquired by Concordia Healthcare corp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top